Breast cancer, with genomic tests 80% of women can avoid chemo

It is recognized as a standard of care and its use is included in all the most important international guidelines on breast cancer, yet Oncotype DX – the test that examines the expression of 21 selected genes on a sample of neoplastic tissue – is struggling to take off in Italy thus depriving many patients of the possibility of avoiding chemotherapy.